









This article has been accepted for publication and undergone full peer review but has not 
been through the copyediting, typesetting, pagination and proofreading process, which may 
lead to differences between this version and the Version of Record. Please cite this article as 
doi: 10.1111/all.13805 
This article is protected by copyright. All rights reserved. 
PROF. OLIVER  PFAAR (Orcid ID : 0000-0003-4374-9639) 
DR. NIKOLAOS G PAPADOPOULOS (Orcid ID : 0000-0002-4448-3468) 
PROF. IOANA  AGACHE (Orcid ID : 0000-0001-7994-364X) 
PROF. CLAUS  BACHERT (Orcid ID : 0000-0003-4742-1665) 
DR. VICTORIA  CARDONA (Orcid ID : 0000-0003-2197-9767) 
PROF. THOMAS B CASALE (Orcid ID : 0000-0002-3149-7377) 
PROF. STEPHEN R. DURHAM (Orcid ID : 0000-0001-5264-6207) 
PROF. WYTSKE WJ FOKKENS (Orcid ID : 0000-0003-4852-229X) 
DR. ROY  GERTH VAN WIJK (Orcid ID : 0000-0002-9608-8742) 
DR. TARI  HAAHTELA (Orcid ID : 0000-0003-4757-2156) 
DR. TOMOHISA  IINUMA (Orcid ID : 0000-0002-9940-5520) 
DR. JÖRG  KLEINE-TEBBE (Orcid ID : 0000-0002-2862-7353) 
PROF. MAREK LESZEK KOWALSKI (Orcid ID : 0000-0002-8442-2774) 
DR. DÉSIRÉE ERLINDA LARENAS-LINNEMANN (Orcid ID : 0000-0002-5713-5331) 
PROF. KARIN C. LØDRUP CARLSEN (Orcid ID : 0000-0002-9257-1198) 
PROF. OLGA  LOURENÇO (Orcid ID : 0000-0002-8401-5976) 
DR. JOAQUIM  MULLOL (Orcid ID : 0000-0003-3463-5007) 
PROF. HAE-SIM  PARK (Orcid ID : 0000-0003-2614-0303) 
PROF. GIOVANNI  PASSALACQUA (Orcid ID : 0000-0002-5139-3604) 
PROF. GRAHAM C ROBERTS (Orcid ID : 0000-0003-2252-1248) 
DR. DERMOT  RYAN (Orcid ID : 0000-0002-4115-7376) 
DR. MOHAMED H SHAMJI (Orcid ID : 0000-0003-3425-3463) 
PROF. ULRICH  WAHN (Orcid ID : 0000-0002-5723-6132) 
PROF. TORSTEN  ZUBERBIER (Orcid ID : 0000-0002-1466-8875) 
 
 




2019 ARIA Care pathways for allergen immunotherapy 
 
Short informative title Many guidelines or national practice guidelines have been 
produced but many are complex and none propose care pathways. 
 
 














This article is protected by copyright. All rights reserved. 
J Bousquet (1, 2)*, O Pfaar (3)*, A Togias (4)**, HJ Schünemann (5), I Ansotegui (6), NG Papadopoulos (7), I 
Tsiligianni (8),  I Agache (9), JM Anto (10-13), C Bachert (14), A Bedbrook (1), KC Bergmann (15), S Bosnic-
Anticevich (16), I Bosse (17), J Brozek (5), M Calderon (18), GW Canonica (19), L Caraballo (20), V Cardona (21), 
T Casale (22), L Cecchi (23), DK Chu (5),  E Costa (24),  AA Cruz (25), W Czarlewski (27), SR Durham (26), G Du 
Toit (27), M Dykewicz (28), M Ebisawa (29), JL Fauquert (30), M Fernandez-Rivas (31), WJ Fokkens (32), J 
Fonseca (33), JF Fontaine (34), R Gerth van Wijk (35), T Haahtela (36), S Halken (37), PW Hellings (38), D 
Ierodiakonou (8), T Iinuma (39), JC Ivancevich (40),  L Jacobsen (41), M Jutel (42), I Kaidashev (43), M Khaitov 
(44), O Kalayci (45), J Kleine Tebbe (46), L Klimek (46), ML Kowalski (47), P Kuna (48), V Kvedariene (49), S La 
Grutta (50), D Larenas-Linemann (51), S Lau (52), D Laune (53), L Le (54), K Lodrup Carlsen (55), O Lourenço 
(56), HJ Malling (57), G Marien (58), E Menditto (59), G Mercier (60), J Mullol (61), A Muraro (62), R O’Hehir 
(63), Y Okamoto (39), GB Pajno (64), HS Park (65), P Panzner (66), G Passalacqua (67), N Pham-Thi (68), G 
Roberts (69), C Rolland (70), N Rosario (71), D Ryan (72), B Samolinski (73), M Sanchez-Borges (74), G Scadding 
(75), MH Shamji (76), A Sheikh (77), GJ Sturm (78), A Todo Bom (79), S Toppila-Salmi (80), M Valentin-Rostan 
(81), A Valiulis (82), E Valovirta (83), MT Ventura (84), U Wahn (85), S Walker (86), D Wallace (87), S Waserman 
(88), A Yorgancioglu (89), T Zuberbier (15) and the ARIA Working Group 
 
 
*: These two authors contributed equally to the paper 
**: Dr. Togias’ co-authorship of this publication does not constitute endorsement by the US National Institute 
of Allergy and Infectious Diseases or by any other United States government agency 
 
 
1. MACVIA-France, Fondation partenariale FMC VIA-LR, Montpellier, France. 
2. INSERM U 1168, VIMA : Ageing and chronic diseases Epidemiological and public health approaches, 
Villejuif, Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France, 
Euforea, Brussels, Belgium, and Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and 
Berlin Institute of Health, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin, 
Germany 
3.   Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University 
Hospital Marburg, Phillipps-Universität Marburg, Germany. 
4. Division of Allergy, Immunology, and Transplantation (DAIT), National Institute of Allergy and Infectious 
Diseases, NIH, Bethesda, US. 
5. Department of Health Research Methods, Evidence and Impact, Division of Immunology and Allergy, 
McMaster University, Hamilton, ON, Canada. 
6. Hospital Quirónsalud Bizkaia, Bilbao, Spain. 
7. Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of 
Manchester, Manchester, UK, and Allergy Department, 2nd Pediatric Clinic, Athens General Children's 










This article is protected by copyright. All rights reserved. 
8. Clinic of Social and Family Medicine, Faculty of Medicine, University of Crete, Crete, Greece. 
9. Faculty of Medicine, Transylvania University, Brasov, Romania. 
10. ISGlobAL, Centre for Research in Environmental Epidemiology (CREAL), Barcelona, Spain. 
11. IMIM (Hospital del Mar Research Institute), Barcelona, Spain. 
12. Universitat Pompeu Fabra  (UPF), Barcelona, Spain. 
13. CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. 
14. Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium. 
15. Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Uniersität zu 
Berlin and Berlin Institute of Health, Comprehensive Allergy-Centre, Department of Dermatology and 
Allergy, member of GA2LEN, Berlin, Germany. 
16. Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and  Local 
Health District, Glebe, NSW, Australia. 
17. Allergist, La Rochelle, France. 
18. Quebec Heart and Lung Institute, Laval University, Québec City, Quebec, Canada. 
19. Calderon. Imperial College London - National Heart and Lung Institute, Royal Brompton Hospital NHS, 
London, UK. 
20. Personalized Medicine Clinic Asthma & Allergy, Humanitas University, Humanitas Research Hospital, 
Rozzano, Milan, Italy   
21. Institute for Immunological Research, University of Cartagena, Campus de Zaragocilla, Colombia, and 
Foundation for the Development of Medical and Biological Sciences (Fundemeb), Cartagena, Colombia. 
22. Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron & ARADyAL research network, 
Barcelona, Spain. 
23. Division of Allergy/Immunology, University of South Florida, Tampa, USA  
24. SOS Allergology and Clinical Immunology, USL Toscana Centro, Prato, Italy. 
25. UCIBIO, REQUIMTE, Faculty of Pharmacy, and Competence Center on Active and Healthy Ageing of 
University of Porto (AgeUPNetWork), University of Porto, Portugal  
26. ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Planning Group, 
Brazil. 
27. Medical Consulting Czarlewski, Levallois, France. 
28. Allergy and Clinical Immunology Section, National Heart and Lung Institute, Imperial College London, UK. 
29. Guy's and st Thomas' NHS Trust, Kings College London, UK. 
30. Section of Allergy and Immunology, Saint Louis University School of Medicine, Saint Louis, Missouri, USA. 
31. Clinical Reserch Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Japan.  
32. Unité de pneumo-allergologie de l'enfant, pôle pédiatrique, CHU de Clermont-Ferrand-Estaing, Clermont-
Ferrand, France. 
33. Allergy Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain. 










This article is protected by copyright. All rights reserved. 
35. CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da 
Universidade do Porto; and Medida, Lda  Porto, Portugal 
36. Allergist, Reims, France. 
37. Department of Internal Medicine, section of Allergology, Erasmus MC, Rotterdam, the Netherlands. 
38. Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland. 
39. Hans Christian Andersen Children's Hospital, Odense University Hospital, Odense, Denmark. 
40. Dept of Otorhinolaryngology, Univ Hospitals Leuven, Belgium, and Academic Medical Center, Univ of 
Amsterdam, The Netherlands and Euforea, Brussels, Belgium. 
41. Dept of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan. 
42. Servicio de Alergia e Immunologia,  Clinica Santa Isabel, Buenos Aires, Argentina. 
43. Allergy Learning and Consulting, Copenhagen, Denmark. 
44. Department of Clinical Immunology, Wrocław Medical University, Poland. 
45. Ukrainian Medical Stomatological Academy, Poltava, Ukraine. 
46. National Research Center, Institute of Immunology, Federal Medicobiological Agency, Laboratory of 
Molecular immunology, Moscow, Russian Federation. 
47. Pediatric Allergy and Asthma Unit, Hacettepe University School of Medicine, Ankara, Turkey. 
48. Allergy & Asthma Center Westend, Berlin, Germany. 
49. Department of Immunology and Allergy, Healthy Ageing Research Center, Medical University of Lodz, 
Poland and Sach's Childrend and Youth Hospital, Södersjukhuset, Stockholm, Sweden  
50. Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, 
Poland. 
51. Institute of Biomedical Sciences, Department of Pathology, Faculty of Medicine, Vilnius University and 
Institute of Clinical medicine, Clinic of Chest diseases and Allergology, faculty of Medicine, Vilnius University, 
Vilnius, Lithuania 
52. Institute of Biomedicine and Molecular Immunology (IBIM), National Research Council (CNR), Palermo, 
Italy. 
53. Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, 
Mexico. 
54. Department of Pediatric Pneumology and Immunology, Charité Universitätsmedizin, Berlin, Germany. 
55. KYomed INNOV, Montpellier, France. 
56. University of Medicine and Pharmacy, Hochiminh City, Vietnam. 
57. Oslo University Hospital, Department of Paediatrics, Oslo, and University of Oslo, Faculty of Medicine, 
Institute of Clinical Medicine, Oslo, Norway. 
58. Faculty of Health Sciences and CICS – UBI, Health Sciences Research Centre, University of Beira Interior, 
Covilhã, Portugal. 
59. Danish Allergy Centre, University of Copenhagen, Copenhagen, Denmark. 
60. EUFOREA, Bussels, Belgium. 
61. CIRFF, Center of Pharmacoeconomics, University of Naples Federico II, Naples, Italy. 










This article is protected by copyright. All rights reserved. 
63. Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic; Clinical & Experimental Respiratory 
Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Spain. 
64. Food Allergy Referral Centre Veneto Region, Department of Women and Child Health, Padua General 
University Hospital, Padua, Italy. 
65. Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, 
Monash University, Melbourne, Victoria, Australia. 
66. Department of Pediatrics, Allergy Unit, University of Messina, Messina, Italy. 
67. Department of Allergy and Clinical Immunology, Ajou University School of Medicine, Suwon, South Korea. 
68. Department of Immunology and Allergology, Faculty of Medicine in Pilsen, Charles University in Prague, 
Pilsen, Czech Republic. 
69. Allergy and Respiratory Diseases, Ospedale Policlino San Martino -University of Genoa, Italy 
70. Allergy department, Pasteur Institute, Paris, France. 
71. David Hide Centre, St Mary's Hospital, Isle of Wight and University of Southampton, Southampton, UK. 
72. Association Asthme et Allergie, Paris, France. 
73. Hospital de Clinicas, University of Parana, Brazil. 
74. Honorary Clinical Research Fellow, Allergy and Respiratory Research Group, Usher Institute of Population 
Health Sciences and Informatics, University of Edinburgh, Medical School, Edinburgh, UK    
75. Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, 
Poland. 
76. Allergy and Clinical Immunology Department, Centro Medico-Docente La Trinidad, Caracas, Venezuela. 
77. The Royal National TNE Hospital, University College London, UK. 
78. Immunomodulation and Tolerance Group, Imperial College London, and Allergy and Clinical Immunology, 
Imperial College London, London, UK. 
79. The Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, 
UK. 
80. Department of Dermatology and Venerology, Medical University of Graz, Graz, Austria and Outpatient 
Allergy Clinic Reumannplatz, Vienna, Austria. 
81. Imunoalergologia, Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of 
Coimbra, Portugal. 
82. Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. 
83. Allergist, Montevideo, Uruguay. 
84. Vilnius University Institute of Clinical Medicine, Clinic of Children's Diseases, and Institute of Health 
Sciences, Department of Public Health, Vilnius, Lithuania; European Academy of Paediatrics (EAP/UEMS-
SP), Brussels, Belgium. 
85. Department of Lung Diseases and Clinical Immunology, University of Turku and Terveystalo allergy clinic, 
Turku, Finland. 
86. University of Bari Medical School, Unit of Geriatric Immunoallergology, Bari, Italy. 










This article is protected by copyright. All rights reserved. 
88. Asthma UK, Mansell street, London, UK. 
89. Nova Southeastern University, Fort Lauderdale, Florida, USA. 
90. Department of Medicine, Clinical Immunology and Allergy, McMaster University, Hamilton, Ontario, 
Canada. 




Address for correspondence 
Professor Jean Bousquet   
CHU Montpellier, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France       
Tel +33 611 42 88 47    jean.bousquet@orange.fr 
 
Conflicts of interest: 
Dr Claus Bachert reports personal fees from Uriach. 
Dr Bosnic-Anticevich reports personal fees from TEVA, Boehringer Ingelheim, Sanofi, AstraZeneca, GSK, grants 
from TEVA, MEDA, outside the submitted work. 
Dr Bousquet reports personal fees and other from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, 
Novartis, Sanofi-Aventis, Takeda, Teva, Uriach, other from Kyomed, outside the submitted work. 
Dr. Cardona reports personal fees from Allergopharma, personal fees from ALK, personal fees from Diater, 
personal fees from Leti, personal fees from Thermofisher, outside the submitted work. 
Dr. Casale reports grants and personal fees from Stallergenes, outside the submitted work. 
Dr. Cecchi reports personal fees from Menarini, Malesci, ALK, outside the submitted work. 
Dr. Cruz reports grants and personal fees from GSK, personal fees and non-financial support from Boehringer 
Ingelheim, Astrazeneca, MEDA, personal fees from Novartis, Boston Scientific, EUROFARMA, non-financial 
support from CHIESI, outside the submitted work. 
Dr. Durham reports personal fees from Adiga, Anergis, ALK, Allergopharma, MedicalUpdate GmBC, UCB, outside 
the submitted work. 
Dr Du Toit reports personal fees from Stallergenes, outside the submitted work.Dr. Ebisawa reports personal 
fees from DBV Technologies, Mylan EPD, maruho, Shionogi & CO., Ltd., Kyorin Pharmaceutical Co., Ltd., 
Thermofisher Diagnostics Pfizer, Beyer, Nippon Chemifar, Takeda Pharmaceutical Co., Ltd., MSD, outside the 
submitted work. 
Dr. Gerth van Wijk reports personal fees from ALK Abello, Allergopharma, outside the submitted work. 
Dr. Haahtela reports personal fees from Orion Pharma, Mundipharma, during the conduct of the study. 
Dr. Hellings reports grants from Mylan, other from Stallergenes, Allergopharma, Sanofi, during the conduct of 
the study; grants from Mylan. 
Dr. Ivancevich reports personal fees from Eurofarma Argentina, Faes Farma, other from Sanofi, Laboratorios 
Casasco, outside the submitted work. 
Dr. Kvedariene reports personal fees from GSK, Berlin CHemie Menarini, non-financial support from 
StallergenGreer, Mylan, AstraZeneca, outside the submitted work. 
Larenas Linnemann reports personal fees from GSK, Astrazeneca, MEDA, Boehringer Ingelheim, Novartis, 
Grunenthal, UCB, Amstrong, Siegfried, DBV Technologies, MSD, Pfizer. grants from Sanofi, Astrazeneca, 
Novartis, UCB, GSK, TEVA, Chiesi, Boehringer Ingelheim, outside the submitted work. 
Dr Okamoto reports personal fees from Shionogi Co. Ltd., Torii Co. Ltd., GSK, MSD, Kyowa Co. Ltd., from Eizai Co. 
Ltd., grants and personal fees from Kyorin Co. Ltd., Tiho Co. Ltd., grants from Yakuruto Co. Ltd., Yamada Bee 
Farm, outside the submitted work. 
Dr Papadopoulos reports personal fees from Abbvie Novartis, Faes Farma, BIOMAY, HAL, Nutricia Research, 
Menarini, Novartis, MEDA, MSD, Omega Pharma, Danone, grants from Menarini, outside the submitted work 










This article is protected by copyright. All rights reserved. 
Dr. Pfaar reports grants and personal fees from ALK-Abelló, Allergopharma, Stallergenes Greer, HAL Allergy 
Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, ASIT Biotech Tools S.A., 
Laboratorios LETI/LETI Pharma, Anergis S.A., grants from Biomay, Nuvo, Circassia, personal fees from Novartis 
Pharma, MEDA Pharma, Mobile Chamber Experts (a GA2LEN Partner), Pohl-Boskamp, Indoor Biotechnologies, 
grants from Glaxo Smith Kline, outside the submitted work. 
Dr. Scadding reports personal fees from ALK, Sequirus, outside the submitted work. 
Dr. Sheikh reports grants from EAACI, outside the submitted work. 
Dr. Todo-Bom reports grants and personal fees from Teva, Mundipharma, personal fees from AstraZeneca, GSK, 
Novartis, grants from Bial, grants from Leti, outside the submitted work. 
Dr. Wallace reports other from ALK, outside the submitted work. 
Waserman reports personnal fees from Merck, GSK, Novartis, Behring, Shire, Sanofi, Barid Aralez, Mylan Meda, 
Pediapharm outside the submitted work. 
Dr. Zuberbier reports and Organizational affiliations: Commitee member: WHO-Initiative "Allergic Rhinitis and 
Its Impact on Asthma" (ARIA). Member of the Board: German Society for Allergy and Clinical Immunology 
(DGAKI). Head: European Centre for Allergy Research Foundation (ECARF) ; Secretary General: Global Allergy 
and Asthma European Network (GA2LEN). Member: Committee on Allergy Diagnosis and Molecular Allergology, 




Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis 
and/or asthma. Many guidelines or national practice guidelines have been produced but the evidence-
based method varies, many are complex and none propose care pathways. This paper reviews care 
pathways for AIT using strict criteria and provides simple recommendations that can be used by all 
stakeholders including health professionals. The decision to prescribe AIT for the patient should be 
individualized and based on the relevance of the allergens, the persistence of symptoms despite 
appropriate medications according to guidelines as well as on the availability of good-quality and 
efficacious extracts. Allergen extracts cannot be regarded as generics. Immunotherapy is selected by 
specialists for stratified patients. There are no currently available validated biomarkers that can 
predict AIT success. In adolescents and adults, AIT should be reserved for patients with 
moderate/severe rhinitis or for those with moderate asthma who, despite appropriate pharmacotherapy 
and adherence, continue to exhibit exacerbations that appear to be related to allergen exposure, except 
in some specific cases. Immunotherapy may be even more advantageous in patients with 
multimorbidity. In children, AIT may prevent asthma onset in patients with rhinitis. mHealth tools are 
promising for the stratification and follow up of patients. 
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Abbreviations 
 
AIT: Allergen immunotherapy 
AR: Allergic rhinitis 
ARIA: Allergic Rhinitis and its Impact on Asthma 
CDSS: Clinical decision support system 
CRD: Chronic respiratory disease 
DB-PC-RCT: Double-blind, placebo-controlled, randomized trial 
EIP on AHA: European Innovation Partnership on Active and Healthy Ageing 
EIT: European Institute for Innovation and Technology 
EU: European Union 
GRADE: Grading of Recommendations Assessment, Development and Evaluation 
ICER: Incremental cost effectiveness ratio 
ICP: Integrated care pathway 
JA-CHRODIS: Joint Action on Chronic Diseases and Promoting Healthy Ageing across the Life Cycle 
MACVIA: Fighting chronic diseases for active and healthy ageing 
MASK-air®: (formerly Allergy Diary) 
MASK: Mobile Airways Sentinel NetworK 
NICE: National Institute for Health and Clinical Excellence (UK) 
PCP: Primary health care professional 
QALY: Quality-adjusted life year  
QOL: Quality-of-life  
RCT: Randomized controlled trials 
RWE: Real-world evidence 
SmPC: Summary of product characteristics 
SCIT: Subcutaneous immunotherapy 
SCUAD: Severe Chronic Upper Airway Disease 
SLIT: Sublingual immunotherapy 
WHO: World Health Organization 
 
Introduction 
In all societies, the burden and cost of allergic diseases are increasing rapidly and “change 
management” strategies are needed to support the transformation of the health care system for 
integrated care. As an example for allergic disease care, the newest ARIA (Allergic Rhinitis and its 
Impact on Asthma) project (ARIA phase 4) (1, 2) and POLLAR (Impact of Air POLLution on 
Asthma and Rhinitis, EIT Health) (3) are proposing digitally-enabled, integrated, person-centred care 
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Integrated Care Pathways (ICPs) are structured multi-disciplinary care plans detailing the key steps of 
patient care (5). They promote the translation of guideline recommendations into local protocols and 
their application to clinical practice  (6, 7). ICPs should integrate recommendations from clinical 
practice guidelines, but they usually enhance recommendations by combining interventions 
iteratively, integrate quality assurance and offer recommendation on the coordination of care.  
Allergen immunotherapy (AIT) is a proven therapeutic option for the treatment of allergic rhinitis 
and/or asthma for many standardized products by sublingual (SLIT) or sub-cutaneous (SCIT) routes 
(8-14). Studies using prescription databases have recently found that the efficacy demonstrated in 
double-blind, placebo-controlled, randomized clinical trials (DB-PC-RCT) translates into real life 
(15). In most countries, AIT is more expensive than other medical treatments for allergic rhinitis (AR) 
and should therefore be considered in patients within a stratified medicine approach (16). Many 
international and national guidelines on AIT (8-14, 17) have been produced but the evidence-based 
method varies, many are complex and none propose ICPs.    
The aim of the present publication is to develop the ARIA ICPs for both SCIT and SLIT that were 
proposed by a EAACI Task Force (18).   
 
1. Development of the document 
The original draft of this document was prepared by JB and was circulated to several authors for 
comments. A questionnaire (Annex 1) was also circulated and the answers were collected.  
The document and the questionnaire answers were reviewed during a meeting including ARIA, EIT 
Health  (POLLAR: Impact of Air POLLution on Asthma and Rhinitis) (3), the European Innovation 
Partnership on Active and Healthy Ageing (19)  and the Global Alliance against Chronic Respiratory 
Diseases (GARD, WHO Alliance) with the participation of major allergy societies and patient’s 
organizations (Paris, December 3, 2018). The meeting was carried out with the support of many 
organizations (Figure 1). 
The final document was approved by the members of the Paris study group and the ARIA working 
group. 
A Pocket Guide has been developed and includes the major recommendations of this document in a 
simple format. It is to be used digitally and in paper form to guide clinical practice for all stakeholders 
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2. Gaps in AIT knowledge 
AIT is an effective treatment but there are many gaps including those identified by AIRWAYS ICPs 
(19, 20) (Table 1) (21). Some of these gaps are the basis for the development of ARIA ICPs for AIT. 
3. Allergens to be used 
a. Relevant extract 
The decision to prescribe AIT for the patient should be based on allergen relevance and on the 
persistence of clinical symptoms, despite appropriate medications according to guidelines, as well as 
on the availability of good-quality extracts.   
Adequate quality is essential for any medicinal product to be eligible for marketing (10, 22). Only 
regulated, standardized allergen extracts that are efficacious and safe should be used for AIT (23, 24).   
b. Extrapolation to untested products  
AIT products have to show efficacy and safety in line with regulatory requirements (25). Allergen 
extracts cannot be regarded as generics. In the EU, each individual product (individual product or 
mixtures), with the exceptions made by EMA (European Medicines Agency)  or PEI (Paul Ehrlich 
Institute), must prove its efficiency (23).     
In some cases, exceptions related to the concept of homologous groups defining allergens with a 
significant clinical important cross-reactivity can be accepted without specific clinical documentation. 
These homologous groups include a range of pollen allergen extracts and house dust mites which are 
defined in the respective EMA guides for allergen products (23).  
There is no evidence that mixing different allergens will have the same effect as separately 
administering individual allergens.   Mixing different allergens can result in a dilutional effect - under 
dosing of the treatment and potential specific allergen degradation - due to enzymatic activity of 
certain allergens (26). The risk of allergic side effects can increase, especially by the degradation, 
when a new batch is used (27). Therefore, the EMA has recommended only to use mixed allergen 
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c. Named Patient Products 
In many countries, Named Patient Products (NPP) are used by practitioners in an effort to apply 
precision treatment to patients. However, this practice requires appropriate confirmatory trials and 
real-world evidence since clinical data with some allergens cannot be directly extrapolated to NPP 
practice. NPPs are marketed on exception from the European legislation on allergen extracts (14, 28).    
d. Polysensitized patients 
Allergic diseases are among the most complex and diverse diseases. Patients are often sensitized (IgE) 
to many allergens (polysensitization), but not all of these sensitizations may be clinically relevant. 
Therefore, it is important to treat the allergies that give rise to allergic symptoms and not the 
sensitizations potentially irrelevant for the patient. There is a broad range of evidence for the clinical 
efficacy of single extracts in polysensitized patients (29-31). 
Instead of mixing extracts, the different allergens can be applied separately (12). However, it has been 
proposed without data that two extracts can be given with a 30-minute interval in two different 
injection spots. By doing so, each allergen can be monitored separately for the local reaction and 
potential systemic side effects.  
In general, the question regarding the efficacy of poly- compared to oligo- or mono-allergen 
immunotherapy in polysensitized patients has not been addressed in carefully designed clinical trials. 
A recent report from an NIH-sponsored international workshop on aeroallergen immunotherapy 
outlines trial concepts to address this important knowledge gap (32). 
 
4. Stratification of allergic patients for AIT 
a. Concept of patient stratification 
Precision medicine aims to customize healthcare with medical decisions, practices, and/or products 
tailored to the individual patient. It also refers to the tailoring of medical treatment to the clinical and 
social characteristics of each patient and not necessarily to genomics (33). The stratification of 
patients into subpopulations is the basis of clinical decision-making for increased diagnostic and 
treatment efficacy (34, 35). Patient stratification also integrates cost trends and social determinant 
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In non-life threatening diseases with a very high prevalence, such as allergic diseases, patient 
stratification is required (i) to identify the best candidates for intervention through complex care 
management, (ii) to reduce the amount of time and resources needed to match the right patient to a 
care management programme and (iii) to optimize costs as some therapeutic interventions cannot be 
administered to all patients. Patient stratification may also help to improve the patient’s engagement 
(37).  
Molecular diagnosis, when used with other tools and patients' clinical records, can help clinicians 
better to select the most appropriate patients and allergens for AIT (38) and, in some cases, predict the 
risk of adverse reactions (39). The pattern of sensitization to allergens could potentially predict the 
efficacy of allergen immunotherapy provided that these immunotherapy products contain a sufficient 
amount of these allergens. Nevertheless, multiplex assay remains a third-level approach, not to be 
used as screening method in current practice (39). 
VAS may be useful also for monitoring AIT effectiveness and medication use as it is easy-to-use and 
also validated for AR control of severity.  It has been used as secondary endpoint in both adul and 
prediatric trials (40, 41) 
The role of precision medicine in selecting an AIT regimen was proposed by an expert meeting (36) 
(Table 2). 
The Flow of Precision Medicine approach in allergic disease has been adapted (Figure 2) from (16) 
and (36). In some instances, AIT can be offered to patients whose AR is controlled by 
pharmacotherapy such as those who may develop thunderstorm-induced asthma (42, 43). AIT should 
also be considered even in moderate AR, particularly (but not necessarily only) in patients who have 
had asthma exacerbations during the pollen season and who live in geographically at-risk regions. 
b. Biomarkers in AIT 
Biomarkers - clinical or laboratory characteristics that reflect biological processes - are essential for 
monitoring the health of patients. They include clinical signs identified by physical examination, 
biological assays, mHealth outcomes, genomic indices, and others that can be objectively measured 
and used as indicators of pathophysiological processes (44). They can be used individually or in 
combination but they need further studies.  
There are currently no validated genetic or blood biomarkers for predicting or monitoring the efficacy 
of AIT at an individual patient level although several candidates have been investigated (45). 
Biomarkers associated with mHealth and a clinical decision support system (CDSS) (46) may change 
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stratification, (ii) clinical trials and real-world evidence, (iii) monitoring efficacy and safety of 
targeted therapies (a critical process for identifying appropriate reimbursement) and (iv) 
implementation of stopping rules (Figure 3).  Clinical stopping rules should be developed for AIT, 
similarly to what is currently considered for biologics in severe asthma, as a guidance for continuing 
or stopping treatment after a short (early stopping rule) or long (late stopping rule) period. As an 
example, a global treatment evaluation after 16 weeks is used as an early stopping rule for 
omalizumab treatment (49, 50). 
c. ARIA  
In ARIA 2008 (16), it was indicated that DB-PC-RCTs have confirmed the efficacy of SCIT and 
SLIT. However, trial-based clinical efficacy is one of the many factors in a clinician’s decision-
making process for the use of AIT, especially since AIT RCTs are  designed to fulfill regulatory 
demands for marketing authorization (51). Before starting AIT, it is essential to appreciate the relative 
value of pharmacotherapy and AIT and the degree of disease control achieved using 
pharmacotherapy. Furthermore, it is important to consider the rest of the patient’s medical history as 
well as his/her social and geographical environment.  The indications for SCIT in ARIA 2008 were 
similar to those published in 1998 (52) and 2001 (53).   
 
5. Economic burden of allergic rhinitis and asthma, and cost-effectiveness of 
AIT 
Allergic diseases place a huge burden on society in terms of high prevalence, morbidity, direct costs 
(health service and drugs prescribed) and indirect costs, in particular those related to presenteeism 
(54). In addition, allergies have an impact on learning and performance at all levels of education (55, 
56). Better care for allergies based on guideline-based treatment would allow substantial savings for 
Europe's economy (55).  
Patients with allergic diseases  may not understand the benefits of treatment, and adherence to 
treatment is poor (47). A substantial proportion of AR patients can be managed by appropriate 
pharmacological treatment (1). However, a subset of patients (10 to 20%) is poorly controlled and is 
ascribed to SCUAD (severe chronic upper airway disease) (57 , 58 , 59).  Patients with asthma tend to 
incur higher rhinitis costs.  
The cost-effectiveness of AIT should be considered for ICPs. However, it varies widely between 
countries and, in some countries such as Japan, the costs of AIT and pharmacotherapy are similar, 
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assessment examined the comparative costs of SLIT and SCIT using the UK cost model (60). A 
benefit from both SCIT and SLIT compared with placebo was consistently demonstrated, but the 
extent of this effectiveness in terms of clinical benefit was considered unclear. The study concluded 
that both SCIT and SLIT may be cost-effective from around six years compared with standard 
treatment using the National Institute for Health and Care Excellence (NICE) cost-
effectiveness threshold of £20,000-30,000 per quality-adjusted life years (QALY) (60, 61). A 
systematic overview showed that the cost-effectiveness of AIT is limited and of low methodological 
quality, but suggests that AIT may be cost-effective for people with AR with or without asthma (62). 
This systematic overview suggested that SLIT and SCIT would be considered cost-effective using the 
NICE cost-effectiveness threshold of £20 000 per QALY (63). Many of these studies were based on 
assumptions of the preventive effect of AIT using prediction models such as the Markov’s model. 
These costs should be compared to biologics in the treatment of severe asthma. Although many 
limitations were identified, NICE proposed that Omalizumab (64), Mepolizumab (65) or Reslizumab 
(66) are likely to be cost-effective in severe asthma at the threshold of £30,000 per QALY. 
However, the cost model of NICE may be questioned as it was developed for diseases impairing 
mobility or for severe diseases and does not take indirect costs (e.g. presenteeism) into account. 
Furthermore, it neglects the potential savings outside the UK health care system which may not be 
generalizable.  
6. Safety 
a. Subcutaneous immunotherapy (SCIT) 
A typical reaction (local reaction) is redness and swelling at the injection site immediately or several 
hours after the injection. Sometimes, sneezing, nasal congestion or hives can occur (systemic 
reactions) (67).  Serious reactions to injections are very rare but require immediate medical attention. 
Symptoms of an anaphylactic reaction can include swelling in the throat, wheezing or tightness in the 
chest, nausea and dizziness. Most serious reactions develop within 30 minutes after the injections and 
it is therefore recommended patients wait in their doctor's office for at least 30 minutes after an 
injection. 
b. Sublingual immunotherapy (SLIT) 
Allergen drops or tablets have a more favorable safety profile than injections. SLIT can be 
administered at home after the first dose is > administered under the supervision of a physician. The 
large majority of adverse events are local (mouth itching, lip swelling, nausea) and spontaneously 
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persistence and impact on the quality of life (68).  In some countries excluding Europe, SLIT tablets 
include a warning about possible severe allergic reactions and adrenaline-auto injectors are > 
routinely recommended. This is not the case in Europe although in the rare event that a general 
allergic reaction occurs after SLIT then the risk/benefit should be reassessed and a decision made 
whether to continue SLIT and if appropriate whether a rescue auto-injector should be provided 
7. Patient’s views  
The patient's perspective should always be considered to enable a customized approach in shared 
decision making. There are contrasting real-life studies assessing the level of knowledge, perceptions, 
expectations and satisfaction about AIT. In two European studies, there was a relatively high degree 
of patient’s perception and satisfaction that corresponded well with the physician's views (69, 70). 
However, most studies report a lack of information from allergic patients and every effort should be 
made to improve communication leading to increased patient knowledge and increased patient 
satisfaction (71, 72). Many AR patients have never heard of AIT  (72). 
Adherence to allergen immunotherapy (AIT) is crucial for its efficacy. SCIT requires regular (often 
monthly) visits, while SLIT is performed with a daily intake of allergen tablets or drops at home. 
Non-adherence to an AIT schedule and premature discontinuation are common problems (73). Results 
from various studies have concluded in controversial results on the rate of AIT adherence. Evidence-
based communication, strategy-patient-centred care, motivational interviewing, and shared-decision 
making underscore the importance of taking time to establish trust, understand patient concerns and 
priorities, and involve the patient in decisions regarding AIT (74). A well-organized allergologist’s 
time schedule not only increases safety but also offers the possibility of close follow-up and an 
increase in patient loyalty (73) 
Information from a medical, economical and legal perspective illustrates the importance of the effort 
for evidence. From the medicolegal standpoint, the application of current medical knowledge, in 
combination with care for the patient’s welfare, should drive daily medical practice. Medical criteria 
need to be prioritized over economic aspects, as physicians need to choose treatments according to the 
commonly acknowledged professional standards. Furthermore, the physician has the obligation to 
inform the patient about treatment options according to professional standards, detailing application 
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8. Pharmacist’s views  
Self-medication to treat AR symptoms is common, and most patients self-manage their AR with few 
interactions with their physician (76). Community pharmacists are the most accessible health 
professionals for the public and AR is one of the most common diseases managed by pharmacists. 
They play an essential role in the management of pharmacotherapy, counselling, disease prevention 
and primary care. In particular, with the availability of non-prescribed medications (OTC) in the 
pharmacy, the community pharmacy is often the first stop for AR management (77, 78). 
AR treatment encompasses three different aspects: avoidance of allergen exposure, pharmacotherapy 
and immunotherapy. The pharmacist intervention can specifically tackle the first two and might be an 
opportunity for patient education in terms of avoidance of allergen exposure, disease information, and 
medication use, especially medication administration and adherence. However, products for allergen 
immunotherapy are available in the pharmacies of many countries and the pharmacist must be well-
informed about this treatment. Moreover, the pharmacist might play an important role in educating 
patients about the commitments involved in immunotherapy and its risks. For example, if patients 
miss several doses of immunotherapy, they may have to restart it. It is therefore important for patients 
to know what is expected up front and the pharmacist can play a significant role in providing this 
information.  
9. General Practitioner’s views 
In many countries, the diagnosis and management of allergic disorders take place almost exclusively 
in primary care that has an essential role in the diagnosis and management of allergic diseases (79, 
80). The continuous, easy to access, and holistic role of primary care can support the identification of 
allergic patients, reassure early diagnosis, and regularly follow up allergic patients for assessment of 
disease control, treatment adjustments and shared-decision making that is patient-centred. However, 
few general practitioners (GPs) receive formal undergraduate or postgraduate training in allergy (81, 
82). Although considered important (80, 83, 84), there are minimal requirements for training and 
certification of subspecialists in allergy (85). Therefore, it is important for GPs to have access to 
training and evidence–based primary care allergy guidelines (86). Although some attempts of ICPs 
have been made (87), close collaboration with specialists for proper and time-efficient referral of 
cases will be beneficial for the patient and the health care system. Clear referral criteria and pathway 
plans should be created, implemented and validated by national circumstances and by cost-efficiency 
evaluation (88). Furthermore, GPs play a major role in patient education, self-medication and shared 
decision making (34, 88, 89),  borrowing good practices from the management of other chronic 
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specialist (90). SCIT could also be done in primary care and although it is associated with some risks, 
these can be minimized when given by trained GPs that carefully select patients in an appropriate 
environment with available primary care facilities for treating systemic anaphylactic reactions (91-
94).  
 
10. Practical approach for patient stratification in AIT 
Shared decision making is required for AIT. Patients should be informed about all possible treatment 
options, benefits and drawbacks of AIT including its duration. Moreover, patients should know 
whether AIT is covered by their health system or insurance company and whether it will generate 
partial out-of-pocket costs or will need to be fully covered out-of-pocket.   
Although biologics in severe asthma and AIT in allergic diseases target two different populations, 
costs per QALY, at least in some European countries, appear to be similar between AIT and 
biologics. This indicates that AIT should be reserved for stratified rhinitis patients insufficiently 
responsive to pharmacologic treatment (e.g. SCUAD (57)) who have been evaluated and guided with 
respect to adherence to pharmacotherapy. For asthma, a similar recommendation applies, but AIT 
should not be considered for severe asthma patients who are candidates for biologics. This 
recommendation is in line with the indications for a house dust mite tablet recently approved by the 
European Medicines Agency (95).  
a. Rhinitis and rhinoconjunctivitis in adolescents and adults 
The selection of pharmacotherapy for AR patients depends on several factors, including age, 
predominant symptoms, severity, AR control, patient preferences and cost. Allergen exposure and 
resulting symptoms vary, e.g., based upon seasonal exposure or change in environment, making it 
necessary to make adjustments to therapy. CDSS may be beneficial by assessing disease control (96). 
They should be based on the best evidence algorithms to aid patients and health care professionals to 
jointly decide on the treatment and its step-up or step-down strategy depending on AR control (shared 
decision making).  
The treatment of AR also requires consideration of (i) the phenotype (rhinitis, conjunctivitis and/or 
asthma) and severity of symptoms, (ii) the relative efficacy of the treatment, (iii) speed of onset of 
action of treatment, (iv) current treatment, (v) historic response to treatment, (vi) patient’s preference, 
(vi) interest to self-manage and (viii) resource use. Guidelines and various statements by experts for 
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All recommended medications are considered to be safe at the usual dosage except first generation 
oral H1-antihistamines which should be avoided (99). Notably, despite guidelines, the practice of 
prescribing both an INCS and an oral H1-antihistamine is globally common. 
For step-up and step-down management, a simple algorithm was devised by MACVIA, but its 
applicability varies depending on the availability of medications and resources in different countries 
(Figure 4) (100).  
Algorithms inherently result from combining individual decision nodes that represent separate 
recommendations. To be fully validated, the algorithm needs to be tested as a complete management 
plan and compared to alternative plans to explore if the combination of these separate 
recommendations leads to more benefit than harm when applied in practice. A large scale mobile 
technology study (47), a speed of onset study (101) and new recommendations supported the 
algorithm (97, 98).   
b. Asthma in adolescents and adults 
An algorithm is not yet available for asthma. Uncontrolled asthma is a contra-indication for AIT 
(102).  
GINA (Global Initiative for Asthma) has endorsed SLIT for house dust mite-asthma (103). From the 
SmPC for the approved SLIT house dust mite  tablet (95): (i) the patient should not have had a severe 
asthma exacerbation within the last 3 months of AIT initiation; (ii) in patients with asthma and 
experiencing an acute respiratory tract infection, initiation of treatment should be postponed until the 
infection has resolved; (iii) AIT is not indicated for the treatment of acute exacerbations and patients 
must be informed of the need to seek medical attention immediately if their asthma deteriorates 
suddenly; (iv) mite AIT should initially be used as an add-on therapy to controller treatment and 
reduction in asthma controllers should be performed gradually under the supervision of a physician 
according to management guidelines.  
No other AIT product has been approved for asthma in the EU. 
c. Multimorbidity 
Multimorbidity, the co-existence of more than one allergic disease in the same patient, is very 
common in allergic diseases and over 85% of patients with asthma also have AR. On the other hand, 
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An advantage of AIT is that it can control many aspects of multimorbidity including AR, asthma and 
conjunctivitis. Although multimorbid patients appear to have more severe symptoms related to each 
component of their allergic disease constellation, it is not yet known whether AIT is equally or more 
effective in these patients, compared to patients with no multimorbidity. This can be tested using 
existing databases, but a controlled trial will also offer useful evidence. In the conditions and 
authorization of a SLIT mite tablet (95), multimorbidity was recognized as an indication for mite 
SLIT. 
d. Children  
In children, AIT is effective as shown by RCTs (105) and may have long-term effects after it is 
stopped (106).  A recent study of SLIT (107), a previous study of subcutaneous grass pollen 
immunotherapy in children (108)  and a meta-analysis (109) have provided some evidence that AIT 
can delay or prevent the onset of asthma in children. However, (i) the meta-analysis showed a limited 
reduced short-term risk of developing asthma in those with AR with unclear benefit over the longer 
term (109), and (ii) costs cannot be supported by health care systems due to the very large number of 
patients who might be treated with uncertainty on cost-effectiveness.  
Thus, AIT can be initiated in children with moderate/severe AR that is not controlled by 
pharmacotherapy. In such children without asthma, the possibility of preventing the onset of asthma 
should be taken into consideration, although more studies are needed for an unreserved indication (9). 
The lower age for initiating AIT has not been clearly established. In many countries, products are 
licensed for children without a lower age limit. Prospective observational trials and/or registries can 
help confirm AIT safety and performance in the youngest recipients, perhaps down to the age of 3 
years. 
AIT is a paradigm for precision medicine, as it takes into account the multitude of sensitization and 
multimorbidity profile of each patient, both cross-sectionally and in relation to their natural history. 
Indirect yet important evidence provides clues about young patients who may benefit the most: (i) the 
severity of respiratory allergic disease is associated with its persistence (110); (ii) epitope spreading 
and development of new sensitizations suggest benefit with early intervention (111); (iii) the effects 
of AR on school performance and education (56) support focusing of treatment on 
developmental/career milestones. Therefore, the consideration of AIT at early time points, using risk 
in addition to severity as a key selection criterion, is expected to maximize impact on the natural 
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More studies are needed to characterize the long-term effects of AIT. Such studies cannot be 
randomized and even less blinded. Therefore, observational approaches, such as registry research, 
need to be used (112).   
In addition, there are opportunities for disease prevention that have not been adequately explored, 
such as primary prevention. We need more evidence on whether AIT may play a role for the 
prevention of allergic sensitization, the first allergic disease (9). Support for such studies needs to 
come from governmental organizations/public sources, in order to identify optimal cost-efficacy 
strategies. 
  e. Allergen immunotherapy in older age adults   
The immunologic and allergic characteristics of older allergic patients differ from those of young and 
middle-aged adults. Limited studies have found that AIT may be effective in this population (113, 
114).  More data are certainly required for a strong recommendation.  At this point, and before 
making the decision to initiate AIT in older patients, physicians need to have strong indications for 
the role of specific allergens in these patients’ AR or asthma and to take into account non-allergic co-
morbidities that may impact on the safety of AIT.    
11. mHealth in the AIT precision medicine approach 
a. Patient stratification 
It is recommended to stratify AR patients who are uncontrolled despite appropriate treatment and 
adherence to treatment (115). This can easily be achieved using electronic diaries obtained by cell 
phones as demonstrated in MASK-air® (2, 3, 47). Such diaries should include the full list of 
medications. After a single year of survey, physicians can assess whether SCUAD is present and 
could initiate AIT if (i) symptoms are associated with pollen season, (ii) adherence to pharmacologic 
treatment is achieved, (iii) the duration of uncontrolled symptoms was long enough and (iv) an impact 
on work or school productivity was observed. Moreover, asthma and eye symptoms can be recorded, 
as in MASK-air® (2) and other Apps allowing to evaluate the role of multimorbidity. 
b. Follow-up of patients under AIT 
The same approach can be proposed for the follow up of patients on AIT to assess its efficacy as 
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c. Electronic clinical decision support system 
The AR algorithm has been digitalized in tablets for health care professionals (46). 
 
Conclusions 
AIT is an effective treatment for allergic diseases caused by inhaled allergens. Its use should, 
however, be restricted to carefully selected patients who are unresponsive to appropriate 
pharmacotherapy according to guidelines and for whom effective and cost-effective AIT is available. 
The present report reviews care pathways for the administration of AIT using evidence-based criteria.  
It is hoped that these recommendations are considered by healthcare professionals, so that the 
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Table 1: Gaps in AIT proposed by AIRWAYS ICPs (modified from (21)) 
• Better understand the role of AIT across the life cycle, particularly in preschool children (prevention and 
treatment) and in the elderly. 
• Increase the awareness of the impact of AIT across the life cycle to promote active and healthy ageing. 
• Stratify patients who benefit the most from AIT in all age groups. 
• Launch a collaboration to develop care pathways for chronic respiratory allergic diseases integrating AIT in 
European countries and regions in the frame of AIRWAYS ICPs. 
• Follow and implement actions and plans suggested by this integrated collaboration. 
• Provide evidence for regulatory decisions including cost-effectiveness.   
• Follow and implement actions and plans suggested by this integrated collaboration, endorsed by national 
(or regional) health authorities. 
• Encourage research strategies for novel approaches and biomarker discovery in AIT 
• Encourage research strategies for ‘responders/no-responders’ in AIT 
 
Table 2: Precision Medicine in the indication of AIT (adapted from (16) and (36)) 
1. Precise diagnosis with history, skin prick tests and/or specific IgE and, if needed, component-resolved in 
vitro diagnosis (CRD) (116). In some rare instances, provocation tests may be needed.  
2. Proven indications: Allergic rhinitis, conjunctivitis and/or asthma. 
3. Allergic symptoms predominantly induced by the relevant allergen exposure. 
4. Patient stratification: Poor control of symptoms despite appropriate pharmacotherapy according to 
guidelines with adherence to treatment during the allergy season and/or the alteration of the natural 
history of allergy. Mobile technology may become of relevant importance to stratify patients (mHealth 
biomarker). 
5. Demonstration of efficacy and safety for the product with relevant trials. 
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Table 3:  Summary of recommendations for the treatment of allergic rhinitis and conjunctivitis 
used in the algorithm (adapted from (100)) 
Overall, GRADE-based AR guidelines agree on some important points (8, 97, 98, 100): 
• Oral or intra-nasal H1-anti-histamines are less effective than intra-nasal corticosteroids (INCS) for the 
control of all rhinitis symptoms. H1-anti-histamines are however effective in many patients with mild 
disease and many patients prefer oral medications than intra-nasal ones. 
• Consensus has not been reached as to the relative efficacy of oral versus intra-nasal H1-anti-histamines. 
• In patients with severe rhinitis, INCS represent the first line treatment. However, they need a few days to 
be fully effective. 
• The combination of oral H1-anti-histamines and INCS does not offer a better efficacy than INCS alone (97, 
98). 
• MPAzeFlu, the combined intranasal FP and Azelastine (Aze) in a single device, is more effective than 
monotherapy and indicated for those patients in whom monotherapy with intranasal glucocorticoid is 
insufficient (117-121) (117-121),  patients with severe AR or those who want rapid symptom relief (97, 98, 
122).  An allergen chamber study has confirmed the speed of onset of the combination (101). 
 
 




Figure 2: Flow of precision medicine for AIT (adapted from (16) and (36)) 
 
Figure 3: Potential Biomarkers for AIT   
 
 
Figure 4: Step-up algorithm in treated patients using visual analogue scale (adolescents 
and adults) (adapted from (100))   
 
The proposed algorithm considers the treatment steps and patient’s preference 
VAS levels in ratio 





































This article is protected by copyright. All rights reserved. 
 
 
 
 
 
